Glaukos says Phase 3 extension study shows Epioxa epi-on corneal cross-linking benefits durable through three years in keratoconus

Bitget2026/10/07 20:05

Glaukos reported topline three-year results from a Phase 3 extension study of Epioxa for keratoconus. Follow-up showed sustained disease stabilization with meaningful vision benefits from a single treatment. Safety held up over three years with no serious events tied to treatment, supporting a favorable long-term profile. Durability data could strengthen the product’s competitive positioning as an epi-on alternative to standard cross-linking procedures. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20261007149511) on October 07, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

New York crude oil OTC price exceeds $91, rising more than 0.1% intraday.

智通财经•2026/10/10 23:16

UK maritime authorities report emergency incident in the Strait of Hormuz

智通财经•2026/10/10 22:46

The U.S. Department of Energy authorizes the Strategic Petroleum Reserve to swap up to 4 million barrels of crude oil.

智通财经•2026/10/10 19:46

ExxonMobil and BP can allocate up to 2 million barrels of crude oil between each other

智通财经•2026/10/10 19:46